Clinical assessment of dysphagia in neurodegeneration (CADN): development, validity and reliability of a bedside tool for dysphagia assessment.

摘要: Screening assessments for dysphagia are essential in neurodegenerative disease. Yet there no purpose-built tools to quantify swallowing deficits at bedside or clinical trials. A quantifiable, brief, easy administer assessment that measures the impact of and predicts presence absence aspiration is needed. The Clinical Assessment Dysphagia Neurodegeneration (CADN) was designed by a multidisciplinary team (neurology, neuropsychology, speech pathology) validated against strict methodological criteria two diseases, Parkinson’s disease (PD) degenerative ataxia (DA). CADN comprises parts, an anamnesis (part one) consumption two). Two-thirds patients were assessed using reference tests, SWAL-QOL symptoms subscale videofluoroscopic has 11 items can be administered scored average 7 min. Test–retest reliability established correlation Bland–Altman plots. 125 with recruited; 60 PD 65 DA. Validity ROC graphs correlations. sensitivity 79 84% specificity 71 69% parts one two, respectively. Significant correlations severity also observed (p < 0.001) small large associations between scores Cutoff identified signal clinically meaningful symptomatology risk aspiration. reliable, valid, easily deployed It thus ideally suited both future multicentre trials